Accuray Exceeds 4,000 Lung Cancer Patients Treated with CyberKnife...( More Than 40000 Patients Treated wi...),Health

More Than 40,000 Patients Treated with CyberKnife Radiosurgery Worldwide

SUNNYVALE, Calif., Nov. 16 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, today announced that its CyberKnife(R) Robotic Radiosurgery System has been used to treat more than 4,000 lung cancer patients worldwide. The company also reported that more than 40,000 patients in total have been treated with CyberKnife radiosurgery for tumors throughout the body.

In April 2007, Accuray announced that the number of lung tumor patients treated with the CyberKnife System had surpassed 2,000. In the span of seven months, that number doubled, demonstrating the growing clinical adoption of this treatment modality in lung cancer care.

This significant growth is due in part to the increasing availability of Accuray's unparalleled lung cancer treatment offerings at CyberKnife centers. These one-of-a-kind offerings include the Synchrony(R) Respiratory Tracking System, which continuously synchronizes radiation beam delivery with the motion of the tumor, and the Xsight(R) Lung Tracking System, which uses the body's internal anatomy to precisely track lung tumors non-invasively. It is expected that this number will continue to increase significantly with the launch of M. D. Anderson's prospective clinical lung study, which Accuray announced last month.

According to the American Cancer Society (ACS), lung cancer is the leading cause of cancer-related deaths in the United States and will account for approximately 29 percent of all cancer deaths in 2007. The ACS projects that more than 213,000 new cases of lung cancer will be discovered this year, accounting for 15 percent of all cancer
'/>"/>